Perspectives on: Local and sustained delivery of angiogenic growth factors

Journal of Bioactive and Compatible Polymers

Volumn 22, Issue 1, 2007, Pages 89-114

  Lee, Hyukjin ^a   Chung, Hyun Jung ^a   Park, Tae Gwan ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Angiogenesis; Growth factors; Sustained delivery; Tissue engineering

Indexed keywords

BIOMATERIALS; PROTEINS;

ANGIOGENESIS; ANGIOGENIC GROWTH FACTORS; TISSUE ENGINEERING;

CONTROLLED DRUG DELIVERY;

ALGINIC ACID; ANGIOGENIC FACTOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ARGINYLGLYCYLASPARTIC ACID; BIOMATERIAL; COLLAGEN; DRUG CARRIER; FIBRIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GELATIN; GROWTH FACTOR; HYALURONIC ACID; MACROGOL; MICROSPHERE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; POLOXAMER; POLYESTER; POLYGLACTIN; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HYDROGEL; MEDICAL RESEARCH; NONHUMAN; REVIEW; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; UNSPECIFIED SIDE EFFECT;

EID: 33845548437     PISSN: 08839115     EISSN: 15308030     Source Type: Journal    
DOI: 10.1177/0883911506073363     Document Type: Review

References (102)

1. Fukuda, S. and Maulik, N. (2004). Angiogenic Strategy for Human Ischemic Heart Disease, Mol. Cell Biochem., 264 (1-2). 143-149.
2. Tarzami, S. T. and Singh, J. P. (2004). Pharmacological Revascularisation in Coronary and Peripheral Vascular Disease, Expert Opin. Investig. Drugs, 13 (10). 1319-1326.
3. Syed, I. S. and Rosengart, T. K. (2004). Therapeutic Angiogenesis, Cardiology, 101 (1-3). 131-143.
4. Mooney, D. J. and Mikos, A. G. (1999). Growing New Organs, Sci. Am., 280: 60-65.
5. Bottaro, D. P., Liemann-Vinson, A. and Heidaran, H. A. (2002). Molecular Signaling in Bioengineered Tissue Microenvironments, Ann. NY Acad. Sci., 961: 143-153.
6. Hariawala, M. D. and Esakof, D. (1996). VEGF Improves Myocardial Blood Flow but Produces EDRF-mediated Hypotension in Porcine Hearts, J. Surg. Res., 63: 77-82.
7. Lazarous, D. F. and Uger, E. F. (1997). Pharmacodynamics of Basic Fibroblast Growth Factor, Cardiovasc. Res., 36: 78-85.
8. Wong, C. and Helgerson, S. (2003). Fibrin-based Biomaterials to Deliver Human Growth Factors, Thromb. Haemost., 89: 573-582.
9. L'Heureux, N. and Auger, F. A. (1993). In Vitro Construction of a Human Blood Vessel from Cultured Vascular Cells, J. Vasc. Surg., 17: 499-509.
10. Draget, K. I. and Smidsrod, O. (1997). Alginate Based New Materials, Int. J. Biol. Macromol., 21: 47-55.
11. Lee, H. and Vacanti, J. P. (2002). Local Delivery of Basic Fibroblast Growth Factor Increases both Angiogenesis and Engraftment of Hepatocytes in Tissue Engineered Polymer Devices, Transplantation, 73: 1589-1589.
12. Hubbell, J. A. (1999). Bioactive Biomaterials, Curr. Opin. Biotechnol., 10: 123-129.
13. Sakiyama, S. E. and Hubbell, J. A. (2000). Development of Fibrin Derivatives for Controlled Release of Heparin-binding Growth Factors, J. Control. Rel., 65: 389-402.
14. Richardson, T. P. and Mooney, D. J. (2001). Polymeric System for Dual Growth Factor Delivery, Nat. Biotechnol., 19: 1029-1034.
15. Seliktar, D. and Hubbell, J. A. (2004). MMP-2 Sensitive, VEGF-bearing Bioactive Hydrogels for Promotion of Vascular Healing, J. Biomed. Mater. Res., 68A (4). 704-716.
16. West, J. L. and Hubbell, H. A. (1999). Polymeric Biomaterials with Degradation Sites for Proteases Involved in Cell Migration, Macromolecules, 32: 241-244.
17. Mann, B. K. and West, J. L. (2001). Smooth Muscle Cell Growth in Photopolymerized Hydrogels with Cell Adhesive and Proteolytically Degradable Domains: Synthetic ECM Analogs for Tissue Engineering, Biomaterials, 22: 3045-3051.
18. Kawasuji, M. (2002). Therapeutic Angiogenesis for Ischemic Heart Disease, Ann. Thorac. Cardiovasc. Surg., 8 (2). 59-61.
19. Hirschi, K. K. and Little, C. D. (2002). Vascular Assembly in Natural and Engineered Tissues, Ann. NY Acad. Sci., 961: 223-242.
20. Carmeliet, P. (2000). Mechanisms of Angiogenesis and Arteriogenesis, Nat. Med., 6: 389-395.
21. Rafii, S. and Lyden, D. (2003). Therapeutic Stem Cell Progenitor Cell Transplantation for Organ Vascularization and Regeneration, Nat. Med., 9: 702-712.
22. Liekens, S. and Neyts, J. (2001). Angiogenesis: Regulators and Clinical Applications, Biochem. Pharmacol., 61: 253-270.
23. Ferrara, N. and LeCouter, J. (2003). The Biology of VEGF and its Receptors, Nat. Med., 9: 669-676.
24. Ferrara, N. (2001). Role of Vascular Endothelial Growth Factor in Regulation of Physiological Angiogenesis, Am. J. Physiol. Cell Physiol., 280: c1358 - c1366.
25. Davies, J. E. (ed.) (2000). Bone Engineering, 137-147, Em Squared, Toronto.
26. Luttun, A. and Carmeliet, P. (2002). Placental Growth Factor (PlGF) and its Receptor Flt-1 (VEGFR-1): Novel Therapeutic Targets for Angiogenic Disorders, Ann. NY Acad. Sc., 979: 80-93.
27. Gerwins, P. and Claesson-Welsh, L. (2000). Function of Fibroblast Growth Factors and Vascular Endothelial Growth Factors and their Receptors in Angiogenesis, Crit. Rev. Oncol. Hematol., 34: 185-185.
28. Li, J. and Kirsner, R. S. (2003). Angiogenesis in Wound Repair: Angiogenic Growth Factors and the Extracellular Matrix, Microsc. Res. Tech., 60: 107-107.
29. Nugent, M. A. and Iozzo, R. V. (2000). Fibroblast Growth Factor-2, Int. J. Biochem. Cell Biol., 32: 115-115.
30. Delli Castelli, M. and Leslie, R. D. (2003). Diabetic Retinopathy: Medical Management and Assessment, Hosp. Med., 64: 400-400.
31. Soker, S. and Atala, A. (2000). Systems for Therapeutic Angiogenesis in Tissue Engineering, World J. Urol., 18: 10-10.
32. Isner, J. M. and Assahara, T. (1999). Therapeutic Angiogenesis, Front. Biosci., 3: e49 - e69.
33. Darland, D. C. and D'Amore, P. A. (2001). TGF is Required for the Formation of Capillary-like Structures in Three-dimensional Cocultures of 10T1/2 and Endothelial Cells, Angiogenesis, 4: 11-11.
34. Dvorak, H. F. and Carvalho, A. C. (1979). Induction of a Fibrin-gel Investment: An Early Event in 10 Hepatocarcinoma Growth Mediated by Tumor-secreted Products, J. Immunol., 122: 166-174.
35. Baird, A. and Bohlen, P. (1992). Isolation and Partial Characterization of an Endothelial Cell Growth Factor from the Bovine Kidney: Homology with Basic Fibroblast Growth Factor, Regul. Pept., 12: 201-213.
36. Esch, F. and Ling, N. (1985). Primary Structure of Bovine Pituitary Basic Fibroblast Growth Factor (FGF) and Comparison with the Amino-Terminal Sequence of Bovine Brain Acidic FGF, Proc. Natl. Acad. Sc., 82: 6501-6511.
37. Connolly, D. T. and Heuvelman, D. (1989). Human Vascular Permeability Factor. Isolation from U937 Cells, J. Biol. Chem., 264: 20017-20024.
38. Unger, E. F. and Shou, M. (1991). Heparin Promotes the Formation of Extracardiac to Coronary Anastomoses in a Canine Model, Am. J. Physiol. Heart Circ. Physiol., 260: h1625 - h1634.
39. Quyyumi, A. A. and Lakatos, E. (1993). Angiogenic Effects of Low Molecular Weight Heparin in Patients with Stable Coronary Artery Disease: A Pilot Study, J. Am. Coll. Cardiol., 22: 635-641.
40. Beck, C. S. (1935). The Development of a New Blood Supply to the Heart by Operation, Ann. Surg., 102: 801-806.
41. Vineberg, A. M. and Pirozynski, W. J. (1966). Experimental Revascularization of the Entire Heart: Evaluation of Epicardiectomy, Omental Graft, and/or Implantation of the Internal Mammary Artery in Preventing Myocardial Necrosis and Death of the Animal, Am. Heart J., 72: 79-93.
42. Connolly, D. T. and Nelson, R. (1989). Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis, J. Clin. Invest., 84: 1470-1478.
43. Pepper, M. S. and Orci, L. (1991). Vascular Endothelial Growth Factor Induces Plasminogen Activators and Plasminogen Activator Inhibitor-1 in Microvascular Endothelial Cells, Biochem. Biophys. Res. Commun., 181: 902-906.
44. Leung, D. W. and Kuang, W. J. (1989). Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen, Science, 246: 1306-1309.
45. Wilting, J. and Weich, H. A. (1992). The Effects of Growth Factors on the Day 13 Chorioallantoic Membrane (CAM): A Study of VEGF165 and PDGF-BB, Anat. Embryol., 186: 251-257.
46. Vajanto, I. and Yla-herttuala, S. (2002). Evaluation of Angiogenesis and Side Effects in Ischemic Rabbit Hindlimbs after Intramuscular Injection of Adenoviral Vectors Encoding VEGF and LacZ, J. Gene Med., 4 (4). 371-380.
47. Epstein, S. E. and Kornowski, R. (2001). Therapeutic Interventions for Enhancing Collateral Development by Administration of Growth Factors, Cardiovasc. Res., 49: 532-542.
48. Lazarous, D. F. and Scheinowitz, M. (1996). Comparative Effects of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor on Coronary Collateral Development and the Arterial Response to Injury, Circulation, 94: 1074-1082.
49. Lee, K. Y. and Mooney, D. J. (2003). Comparison of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis in SCID Mice, J. Control. Rel., 87: 49-56.
50. Albini, A. and Noonan, D. M. (2000). Inhibition of Angiogenesis and Vascular Tumor Growth by Interferon-producing Cells, Am. J. Pathol., 156: 1381-1381.
51. Isner, J. M. (2002). Myocardial Gene Therapy, Nature, 415: 234-239.
52. Whitelock, J. M. and Underwood, P. A. (1996). The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelyson, Collagenase, Plasmin, and Heparanases, J. Biol. Chem., 271: 10079-11086.
53. Hung, W. S. and Tsai, Y. H. (2001). Effect of SACCHACHITIN on Keratinocyte Proliferation and the Expression of Type I Collagen and Tissue Transglutaminase During Skin Wound Healing, J. Biomed. Mater. Res., 56: 93-93.
54. Ramirez, F. and Rifkin, D. B. (2003). Cell Signaling Events: A View from the Matrix. Matrix Biol., 22: 101-107.
55. Whitelock, J. M. and Underwood, P. A. (1996). The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases, J. Biol. Chem., 271: 10079-11086.
56. Shelly, E. and Hubbell, J. A. (2000). Development of Fibrin Derivatives for Controlled Release of Heparin-binding Growth Factors, J. Control. Rel., 65: 389-402.
57. Sahni, A. and Francis, C. W. (1999). Potentiation of Endothelial Cell Proliferation by Fibrin(ogen)-bound Fibroblast Growth Factor-2, J. Biol. Chem., 274: 14936-14941.
58. Sahni, A. and Francis, C. W. (2000). Fibrinogen and Fibrin Protect Fibroblast Growth Factor-2 from Proteolytic Degradation, Thromb. Haemost., 83: 736-741.
59. L'Heureux, N. and Auger, F. A. (1993). In Vitro Construction of a Human Blood Vessel from Cultured Vascular Cells: a Morphologic Study, J. Vasc. Surg., 17: 499-509.
60. Auger, F. A. and Germain, L. (1995). Skin Equivalent Produced with Human Collagens, In Vitro Cell Dev. Biol. Anim., 31: 432-429.
61. Tabata, Y. and Ikada, T. (2000). Controlled Release of Vascular Endothelial Growth by Use of Collagen Hydrogels, J. Biomater. Sci. Polymer Edn., 11: 915-915.
62. Pieper, J. S. and Kuppevelt, T. H. (2002). Loading of Collagen-heparan Sulfate Matrices with bFGF Promotes Angiogenesis and Tissue Generation in Rats, J. Biomed. Mater. Res., 62: 185-194.
63. Yamanoto, M. and Tabata, T. (2001). Controlled Release of Growth Factors Based on Biodegradation of Gelatin Hydrogel, J. Biomater. Sci. Polymer Edn., 12: 77-77.
64. Smidsrod, O. and Skjak-Braek, G. (1990). Alginate as Immobilization Matrix for Cells, Trends Biotechol., 8: 71-78.
65. Ostterlei, M. and Espevik, V. (1991). Induction of Cytokine Production from Human Monocytes Stimulated with Alginate, J. Immunother., 10: 286-291.
66. Schuch, G. and Soker, S. (2002). In Vivo Administration of Vascular Endothelial Growth Factor (VEGF) and its Antagonist, Soluble Neuropilin-1, Predicts a Role of VEGF in the Progression of Acute Myeloid Leukemia In Vivo, Blood, 100: 4622-4628.
67. Dons, E. C. and Plunkett, M. L. (1992). Calcium Alginate Beads as a Slow-release System for Delivering Angiogenic Molecules In Vivo and In Vitro, J. Cell Physiol., 152: 422-429.
68. Tanihara, M. and Mizushima, Y. (2001). Sustained Release of Basic Fibroblast Growth Factor and Angiogenesis in a Novel Covalently Crosslinked Gel of Heparin and Alginate, J. Biomed. Mater. Res., 56: 216-216.
69. Forrester, J. V. and Balasz, E. A. (1980). Inhibition of Phagocytosis by High Molecular Weight Hyaluronate, Immunology, 40: 435-446.
70. Kujawa, M. J. and Caplan, A. I. (1986). Substrate-bonded Hyaluronic Acid Exhibits a Size-dependent Stimulation of Chondrogenic Differentiation, Dev. Biol., 144: 519-528.
71. Goldberg, R. L. and Toole, B. P. (1987). Hyaluronate Inhibition of Cell Proliferation, Arthritis Rheum., 30: 769-778.
72. Forrester, J. V. and Balasz, E. A. (1980). Inhibition of Phagocytosis by High Molecular Weight Hyaluronate, Immunology, 40: 435-446.
73. Kujawa, M. J. and Caplan, A. O. (1986). Substrate-bounded Hyaluronic Acid Exhibits a Size-dependent Stimulation of Chondrogenic Differentiation of Stage 24 Limb Mesenchymal Cells in Culture, Dev. Biol., 144: 519-528.
74. Montesano, R. and Pepper, M. S. (1996). Synergistic Effect of Hyaluronan Oligosaccharides and Vascular Endothelial Growth Factor on Angiogenesis In Vitro, Lab. Invest., 75: 259-266.
75. Peattie, R. A. and Prestwich, G. D. (2004). Stimulation of In Vivo Angiogenesis by Cytokine Loaded Hyaluronic Acid Hydrogel Implants, Biomaterials, 25: 2789-2798.
76. Bulpitt, P. and Aeschlimann, D. (1999). New Strategy for Chemical Modification of Hyaluronic Acid, J. Biomed. Mater. Res., 47 (2). 152-169.
77. Levenberg, S. and Langer, R. (2004). Advance in Tissue Engineering, Curr. Top. Dev. Biol., 61: 113-134.
78. Ratner, B. D. and Bryant, S. J. (2004). Biomaterials: Where We Have Been Where We Are Going, Annu. Rev. Biomed. Eng., 6: 41-75.
79. Nam, Y. S. and Park, T. G. (1999). Porous Biodegradable Polymeric Scaffolds Prepared by Thermally Induced Phase Separation, J. Biomed. Mater. Res., 47: 8-17.
80. King, T. W. and Patrick, C. W. (2000). Development and In Vitro Characterization of Vascular Endothelial Growth Factor (VEGF)-loaded Poly(DL-lactic-co-glycolic acid)/Poly(ethylene glycol) Microspheres Using a Solid Encapsulation/Single Emulsion/Solvent Extraction Technique, J. Biomed. Mater. Res., 51: 383-383.
81. Park, T. G. (1995). Degradation of Poly(lactic-co-glycolic acid) Microspheres: Effect of Copolymer Composition, Biomaterials, 16: 1123-1130.
82. Kim, H. K. and Park, T. G. (2004). Comparative Study on Sustained Release of Human Growth Hormone from Semi-crystalline Poly(L-lactic acid) and Amorphous Poly(D, L-lactic-co-glycolic acid) Microspheres: Morphological Effect on Protein Release, J. Control. Rel., 98: 115-125.
83. Park, T. G. (1994). Degradation of Poly(D, L-lactic acid) Microspheres: Effect of Molecular Weight, J. Control. Rel., 30: 161-173.
84. Bouhadir, K. H. and Mooney, D. J. (2001). Promoting Angiogenesis in Engineered Tissues, J. Drug Target., 9: 397-397.
85. Nam, Y. S., Yoon, J. J. and Park, T. G. (2000). A Novel Fabrication Method for Macroporous Scaffolds Using Gas Foaming Salt as Porogen Additive, J. Biomed. Mater. Res. (Appl. Biomat.), 53: 1-7.
86. Sheridan, M. and Mooney, D. J. (2000). Bioabsorbable Polymer Scaffolds for Tissue Engineering Capable of Sustained Growth Factor Delivery, J. Control. Rel., 64: 91-91.
87. Kim, H. K. and Park, T. G. (1999). Microencapsulation of Human Growth Hormone within Biodegradable Polyester Microspheres: Protein Aggregation Stability and Incomplete Release Mechanism, Biotech. Bioeng., 65: 659-667.
88. Sakakibara, Y. and Tabata, T. (2003). Toward Surgical Angiogenesis Using Slow-released Basic Fibroblast Growth Factor, Eur. J. Cardiothorac. Surg., 24: 105-105.
89. Cleland, J. L. and Cuthbertson, A. (2001). Development of Poly-(D, L-lactide-co-glycolide) Microsphere Formulations Containing Recombinant Human Microspheres Using a Rat Model, J. Control. Rel., 72: 13-24.
90. Kim, T. K. and Burgess, D. J. (2002). Pharmacokinetic Characterization of 14C-vascular Endothelial Growth Factor Controlled Release Microspheres Using a Rat Model, J. Pharm. Pharmacol., 54: 897-905.
91. Crotts, G. and Park, T. G. (1998). Protein Delivery from Poly(lactic-co-gly-colic acid) Biodegradable Microspheres: Release Kinetics and Stability Issues, J. Microencapsulation, 15: 699-713.
92. Lee, H. and Park, T. G. (2002). Preparation and Characterization of Mono-PEGylated Epidermal Growth Factor: Evaluation of In Vitro Biological Activity, Pharmaceut. Res., 19: 845-851.
93. Kim, T. H., Lee, H. and Park, T. G. (2002). Pegylated Recombinant Human Epidermal Growth Factor (rhEGF) for Sustained Release from Biodegradable PLGA Microspheres, Biomaterials, 23: 2311-2317.
94. Cruise, G. M. and Hubbell, J. A. (1998). Characterization of Permeability and Network Structure of Interfacially Photopolymerized Poly(ethylene glycol) Diacrylate Hydrogels, Biomaterials, 19: 1287-1294.
95. Bryant, S. J. and Anseth, K. S. (2001). The Effects of Scaffold Thickness on Tissue Engineered Cartilage in Photocrosslinked Poly(ethylene oxide) Hydrogels, Biomaterials, 22: 619-626.
96. Huh, K. M. and Bae, T. G. (1999). Synthesis and Characterization of Poly(ethylene glycol)/Poly(L-lactic acid) Alternating Multiblock Copolymers, Polymer, 40: 6147-6155.
97. Metters, A. T. and Anseth, K. S. (2000). Fundamental Studies of a Novel, Biodegradable PEG-b-PLA Hydrogel, Polymer, 41: 3993-4004.
98. Richardson, T. P. and Mooney, D. J. (2001). Polymeric Systems for Dual Growth Factor Delivery, Nat. Biotechnol., 19: 1029-1034.
99. Holland, T. A. and Mikos, A. G. (2005). Dual Growth Factor Delivery from Degradable Oligo(poly(ethylene glycol) fumarate) Hydrogel Scaffolds for Cartilage Tissue Engineering, J. Control. Release, 3: 101 (1-3). 111-125.
100. Cao, R. and Cao, Y. (2003). Angiogenic Synergism, Vascular Stability and Improvement of Hind-limb Ischemia by a Combination of PDGF-BB and FGF-2, Nat. Med., 9: 604-613.
101. Calza, L. and Levi-Montalcini, R. (2001). Nerve Growth Factor Control of Neuronal Expression of Angiogenic and Vasoactive Factors, Proc. Natl. Acad. Sci., 98: 4160-4165.
102. Kim, M. R. and Park, T. G. (2002). Temperature-responsive and Degradable Hyaluronic Acid/Pluronic Composite Hydrogels for Controlled Release of Human Growth Hormone, J. Control. Rel., 80 (1-3). 69-77.